VistaGen Therapeutics Receives Hong Kong Patent for Methods of Production for AV-101
November 29 2018 - 7:30AM
New Hong Kong patent complements
counterpart patents previously issued in China, Europe and the
U.S.
VistaGen Therapeutics (NASDAQ: VTGN), a clinical-stage
biopharmaceutical company developing new generation medicines for
central nervous system (CNS) diseases and disorders with high unmet
need, today announced that the Hong Kong Patents Registry
Intellectual Property Department has granted a patent related to
certain methods of production for AV-101, VistaGen’s oral NMDA
(N-methyl-D-aspartate) receptor glycine B antagonist in Phase 2
development for adjunctive treatment of major depressive disorder
(MDD).
The new Hong Kong patent (No. 1218414) is the counterpart to
previously issued U.S. Patent No. 9,834,801, European Patent
No. EP2970097, and Chinese Patent No. ZL201480023992.8 and will not
expire until at least 2034.
Shawn Singh, Chief Executive Officer of VistaGen, stated,
“Receiving this patent in Hong Kong, along with its counterpart
patent in China, strengthens our commercial protection in two key
markets in Asia and is another significant step forward in our
global IP plan for AV-101.”
About VistaGen VistaGen Therapeutics, Inc. is a
clinical-stage biopharmaceutical company developing new generation
medicines for multiple CNS diseases and disorders with high unmet
need. For more information, please
visit www.vistagen.com and connect with VistaGen
on Twitter, LinkedIn and Facebook.
About AV-101 AV-101 is an investigational,
oral, NMDA (N-methyl-D-aspartate) receptor glycine B antagonist
with the potential to be a treatment for multiple CNS indications
with high unmet need. AV-101 is currently in Phase 2 clinical
development in the United States for adjunctive treatment of
MDD. The FDA has granted Fast Track designation for
development of AV-101 as both a potential adjunctive treatment of
MDD and as a non-opioid treatment for neuropathic pain.
Forward-Looking Statements This release
contains various statements concerning VistaGen's future
expectations, plans and prospects, including without limitation,
our expectations regarding development and commercialization of our
drug candidates, including AV-101 for adjunctive treatment of MDD
and as a non-opioid treatment for neuropathic pain, as well as our
intellectual property and commercial protection of AV-101, all of
which constitute forward-looking statements for the purposes of the
safe harbor provisions under the Private Securities Litigation
Reform Act of 1995. These forward-looking statements are neither
promises nor guarantees of future performance and are subject to a
variety of risks and uncertainties, many of which are beyond our
control, and may cause actual results to differ materially from
those contemplated in these forward-looking statements. Among these
risks is the possibility that (i) we may encounter unexpected
adverse events in patients during our clinical development of any
product candidate that cause us to discontinue further development,
(ii) we may not be able to successfully demonstrate the safety and
efficacy of our product candidates at each stage of clinical
development, (iii) success in preclinical studies or in early-stage
clinical trials may not be repeated or observed in ongoing or
future studies, and ongoing or future preclinical and clinical
results may not support further development of, or be sufficient to
gain regulatory approval to market our drug candidates, (iv)
decisions or actions of regulatory agencies may negatively affect
the progress of, and our ability to proceed with, further clinical
studies or to obtain marketing approval for our drug candidates,
(v) we may not be able to obtain or maintain adequate intellectual
property protection and other forms of marketing and data
exclusivity for our product candidates, (vi) we may not have access
to or be able to secure substantial additional capital to support
our operations, including our ongoing clinical development
activities, and (vii) we may encounter technical and other
unexpected hurdles in the manufacturing and development of any of
our product candidates. Certain other risks are more fully
discussed in the section entitled "Risk Factors" in our most recent
annual report on Form 10-K, and subsequent quarterly reports on
Form 10-Q, as well as discussions of potential risks,
uncertainties, and other important factors in our other filings
with the Securities and Exchange Commission (SEC). Our SEC filings
are available on the SEC's website at www.sec.gov. In
addition, any forward-looking statements represent our views only
as of the issuance of this release and should not be relied upon as
representing our views as of any subsequent date. We explicitly
disclaim any obligation to update any forward-looking
statements.
Company Contact Mark A. McPartland VistaGen
Therapeutics Inc. Phone: +1 (650) 577-3600
Email: IR@vistagen.com
Investor Contact Valter Pinto / Allison Soss
KCSA Strategic Communications Phone: +1 (212) 896-1254/+1 (212)
896-1267 Email: VistaGen@KCSA.com
Media Contact Caitlin Kasunich / Lisa Lipson
KCSA Strategic Communications Phone: +1 (212) 896-1241/+1 (508)
843-6428 Email: VistaGen@KCSA.com
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From Apr 2024 to May 2024
VistaGen Therapeutics (NASDAQ:VTGN)
Historical Stock Chart
From May 2023 to May 2024